BofA analyst Michael Ryskin lowered the firm’s price target on Bruker (BRKR) to $76 from $80 and keeps a Buy rating on the shares. The firm raised its Q4 estimates to account for “solid” BSI bookings after Bruker provided preliminary Q4 results and FY25 guidance ahead of an investor conference, but lowered its FY25 estimates to account for headwinds from a strong U.S. dollar and adjusted FY25-27 estimates to incorporate FY25 guidance and management commentary.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BRKR:
- U.S. places new export controls on biotech equipment, Reuters reports
- Bruker Shares Limited Information Under SEC Regulations
- Bruker sees Q4 revenue $970M-$980M, consensus $962.89M
- Bruker ‘respectfully disagrees’ with District Court, to seek stay of injunction
- 10x Genomics secures permanent injunction in Bruker patent infringement lawsuit